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Abstract
Background: Microglial function is modulated by several factors reflecting the numerous receptors expressed on
the cell surface, however endogenous factors which contribute to the age-related increase in microglial activation
remain largely unknown. One possible factor which may contribute is interferon-g (IFNg). IFNg has been shown to
increase in the aged brain and potently activates microglia, although its endogenous cell source in the brain
remains unidentified.
Methods: Male Wistar rats were used to assess the effect of age and amyloid-b (Ab) on NK cell infiltration into the
brain. The effect of the anti-inflammatory compound, atorvastatin was also assessed under these conditions. We
measured cytokine and chemokine (IFNg, IL-2, monocyte chemoattractant protein-1 (MCP-1) and IFNg-induced
protein 10 kDa (IP-10)), expression in the brain by appropriate methods. We also looked at NK cell markers, CD161,
NKp30 and NKp46 using flow cytometry and western blot.
Results: Natural killer (NK) cells are a major source of IFNg in the periphery and here we report the presence of
CD161
+ NKp30
+ cells and expression of CD161 and NKp46 in the brain of aged and Ab-treated rats. Furthermore,
we demonstrate that isolated CD161
+ cells respond to interleukin-2 (IL-2) by releasing IFNg. Atorvastatin, the HMG-
CoA reductase inhibitor, attenuates the increase in CD161 and NKp46 observed in hippocampus of aged and Ab-
treated rats. This was paralleled by a decrease in IFNg, markers of microglial activation and the chemokines, MCP-1
and IP-10 which are chemotactic for NK cells.
Conclusions: We propose that NK cells contribute to the age-related and Ab-induced neuroinflammatory changes
and demonstrate that these changes can be modulated by atorvastatin treatment.
Background
Microglia express a vast array of receptors [1] indicative
of the many factors which can increase their activation.
One of the most potent activators of microglia is IFNg
and its concentration has been shown to increase in the
brain of aged, Ab-treated and LPS-treated animals [2,3].
IFNg may act as an endogenous activator of microglial
activation but whether it can be released from resident
cells in the brain is not clear, although it has been
reported that it is produced by microglia of Toxoplasma
gondii-infected severe combined immunodeficiency
(scid) mice [4].
Natural killer (NK) cells are involved in immune sur-
veillance and responsible for the initial response to viral
and pathogenic infection. They express receptors for
several cytokines including IL-2 which triggers cell pro-
liferation, cytotoxic activity and release of cytokines,
including IFNg [5].
Statins, inhibitors of HMG-CoA reductase, suppress
IL-2-induced cytotoxicity of NK cells [6] and attenuate
the age-related and Ab-induced microglial activation,
and accompanying increase in IFNg [3,7]. Here we
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any medium, provided the original work is properly cited.investigated the possibility that IFNg released by infil-
trating CD161
+ cells might contribute to microglial acti-
vation in 2 neuroinflammatory models, the aged rat and
the Ab-treated rat. We also investigated whether the
modulating effect of atorvastatin may be a consequence
of its ability to interfere with release of IFNg from these
infiltrating cells. The evidence presented here suggests
that IFNg plays a role in the age-related and Ab-induced
increase in microglial activation and that the source of
the IFNg is CD161
+ cells. Importantly, treatment with
atorvastatin decreases CD161 and NKp46 (a specific NK
cell marker) in the hippocampus of aged and Ab-treated
animals and consequently decreases the changes in IFNg
and microglial activation.
Methods
Animals and study design
Male Wistar rats (Bantham and Kingman, UK; n = 5-7)
aged 3 months (250-350 g) or 22 months (550-650 g),
housed in pairs or groups of 4 respectively. All these
experiments were performed under license (Department
of Health, Ireland) and in accordance with local ethical
guidelines.
In the first study, young and aged rats were anaesthe-
tized with urethane (1.5 g/kg intraperitoneally) and
transcardially perfused with 200-300 ml saline before tis-
sue was harvested. In the second study, young and aged
rats (n = 5-7) were divided into a control group and a
group that received atorvastatin orally (5 mg/kg per day)
for 8 weeks. Mean body weights of young animals (g)
before and after treatment were 222 ± 9 and 356 ± 15
in the control group and 219 ± 7 and 340 ± 13 in the
atorvastatin-treated group; the corresponding weights in
aged rats were 534 ± 17 and 555 ± 22 (controls) and
527 ± 16 and 577 ± 22 (atorvastatin). In the third study,
young rats, assigned to a control- or an Ab-treated
group, were subdivided into rats which did/did not
receive atorvastatin (5 mg/kg per day) for 3 weeks;
mean body weights (g) before and after treatment were
291 ± 12 and 337 ± 9 in the control group and 277 ±
13 and 336 ± 15 in the atorvastatin-treated group.
Ground atorvastatin calcium tablets (Lipitor™;P f i z e r -
Parke Davis, Ireland) were dissolved in vegetable oil
(5 ml/150 g chow) and added to laboratory chow (Red
Mills, Ireland); control animals received laboratory chow
with added vegetable oil. The dose of atorvastatin was
chosen on the basis of previous findings [3,8]. Food
intake (18 g and 25 g per rats per day for young and
aged rats respectively) was assessed before and during
the study to ensure animals received their full atorvasta-
tin dose and fresh food was prepared every 2 days.
Mean atorvastatin concentrations (± SEM; ng ATV/mg
protein) in plasma and liver respectively were 0.008 ±
0.002 in young rats and 0.005 ± 0.002 in aged rats, and
0.026 ± 0.05 in young rats and 0.020 ± 0.05 in aged rats.
Ab1-42 (5 μl; 200 μM; aggregated for 48 hours at 37°C;
Biosource International Inc. US) or vehicle was delivered
intracerebroventricularly (2.5 mm posterior and 0.5 mm
lateral to bregma; depth 3.5 mm) to urethane-anaesthe-
tized rats [7], on the last day of atorvastatin treatment.
[We have previously established that treatment of ani-
mals with reverse peptide, Ab40-1 exerted no effect on
hippocampal expression of MHCII, CD40 or CD11b
mRNA, or on hippocampal IL-1b at mRNA or protein
level]. Rats were killed 4 hours after Ab injection [7],
the hippocampus was dissected and used for preparation
of dissociated cells by flow cytometry or for analysis of
mRNA or for western immunoblot.
Assessment of NK cells by flow cytometry
Following transcardial perfusion hippocampal tissue was
harvested and passed through a cell strainer (70 μm)
and centrifuged (170 × g, 10 min). The pellet was resus-
pended in PBS containing collagenase D (1 mg/ml) and
DNase I (200 μg/ml), incubated at 37°C for 30 min and
centrifuged (170 × g, 5 min). Pellets were resuspended
in 1.088 g/ml Percoll (9 ml), underlaid with 1.122 g/ml
Percoll (5 ml), and overlaid with 1.072 g/ml and 1.030
g/ml (9 ml each) Percoll and PBS (9 ml) and centrifuged
(1250 × g, 45 min). The mononuclear cells (between the
1.088:1.072 and 1.072:1.030) were centrifuged and the
pellets were washed, and blocked for 15 min at room
temperature in FACS block (Mouse BD Fc Block (BD
Pharmingen, UK); 1:500 in FACS buffer). Cells were
incubated with CD161a-FITC (1:100 in FACS buffer; BD
Biosciences, UK) and NKp30-PE (1:30 in FACS buffer;
Santa Cruz Biotechnology Inc, USA). Immunofluores-
cence analysis was performed on a DAKO Cyan ADP 7
colour flow cytometer (DAKO Cytomation, UK) with
Summit v4.3 software.
Isolation of NK cells
IgG-precoated magnetic beads (100 μl; 4 × 10
6 beads;
monoclonal human anti-mouse IgG; Invitrogen, UK)
were incubated overnight at 4°C with mouse anti-rat
CD161 primary antibody (1 mg/ml: Serotec, UK) or
mouse IgG (0.4 mg/ml; Santa Cruz, USA). Perfused hip-
pocampal or cortical tissue was triturated in pre-warmed
DMEM (Gibco BRL, Scotland), centrifuged (2000 × g,
4 min) and trypsinized (Tryple Express; Invitrogen, UK;
2 min, RT). Cells were centrifuged (2000 × g, 4 min),
resuspended in DMEM and filtered 3 times, incubated
with CD161-coated or IgG-coated beads (2 hours, 4°C)
and collected by magnetic isolation. Cell isolation was
checked by gel electrophoresis, and visualized following
western immunoblot using a monoclonal anti-CD161
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IFNg was assessed in supernatants.
In another experiment, a human NK cell line was
grown in RPMI with glutamax (Gibco, UK) supplemen-
ted with foetal calf serum (10%; Gibco, UK), penicillin
(100 U/ml; Gibco, UK), streptomycin (100 μg/mg;
Gibco, UK) and IL-2 (20 ng/ml; R&D Systems, UK).
Cells were washed (1200 g × 10 min) 3 times, resus-
pended in warmed media and incubated for 24 hours in
the presence/absence of IL-2 (20 ng/ml). Supernatants
were assessed for IFNg by ELISA.
Preparation of mixed glial cultures
Primary cortical mixed glia were prepared from 1 day
old male Wistar rats as previously described [2]. Briefly
cortical tissue was chopped, incubated for 5 minutes in
5% CO2 at 37°C in warm filter-sterilized Dulbecco’s
Modified Eagle Medium (DMEM; Sigma Aldrich, UK)
supplemented with penicillin (100 μl/ml; Gibco, UK),
streptomycin (100 μl/ml; Gibco, UK) and FBS (10% w/v;
Gibco, UK). A single cell suspension was prepared by
triturating tissue, filtering though a 40 μm sterile nylon
mesh filter (BD Biosciences, USA), centrifuging at
2000 g for 3 minutes at 20°C, and resuspending the
pellet 1 ml warm filter-sterilized culture media. Tissue
was triturated and resuspended glia were counted, equal
numbers of cells were plated onto 6 well plates and
incubated for 2 hours in 5% CO2 at 37°C to allow the
cells to adhere. After 2 hours the cells were flooded
with 1 ml warm culture media and incubated for 3 days
in 5% CO2 at 37°C. Culture media was replaced with
fresh culture media every 3 days for 12 days until cells
were ready for treatments. After 12 days in culture, cells
were incubated in the presence or absence of IFNg
(50 ng/ml; 24 hours at 37°C; R&D Systems, UK). This
concentration has been shown to robustly increase
MHCII mRNA [9]. Cells were harvested for analysis of
MHCII and CD11b mRNA.
Real-time PCR
Total RNA was extracted from snap-frozen hippocampal
tissue or cultured glial cells using a NucleoSpin
® RNAII
isolation kit (Macherey-Nagel Inc., Germany). Total
RNA concentrations were determined by spectrophoto-
metry, samples were equalised and cDNA synthesis was
performed on 1 μg total RNA using a High Capacity
cDNA RT kit (Applied Biosystems, Germany). Real-time
PCR was performed using Taqman Gene Expression
Assays (Applied Biosystems, Germany); the assay
IDs for MHCII, CD11b, MCP-1 and IP-10 were
Rn01768597_m1, Rn00709342_m1, Rn00580555_m1 and
Rn00594648_m1, respectively. Real-time PCR was
conducted using an ABI Prism 7300 instrument
(Applied Biosystems, Germany). A 20 μlv o l u m ew a s
added to each well (9 μl of diluted cDNA, 1 μl of primer
and 10 μlo fT a q m a n
® Universal PCR Master Mix).
Samples were assayed in duplicate (40 cycles; 95°C for
10 min, 95°C for 15 sec for each cycle (denaturation)
and the transcription step at 60°C for 1 min). b-actin
was the endogenous control (VIC-labeled MGB Taqman
probe, Applied Biosystems, Germany; Assay ID:
4352341E). Gene expression was calculated relative to
the endogenous control samples and to the control sam-
ple giving an RQ value (2
- DDCt, where CT is the thresh-
old cycle)
Analysis of CD161 and NKp46 by western blot
Hippocampal tissue was equalized for protein, aliquots
(10 μl) were loaded onto 10% gels, separated (30 mA;
60 min) and transferred onto nitrocellulose (225 mA;
90 min). Proteins were immunoblotted over night hours
at 4°C with anti-CD161 antibody (1:500 in TBS con-
taining 0.05% Tween-20/2% BSA; Serotec, UK) or anti-
NKp46 antibody (1:500 in TBS containing 0.05%
Tween-20/2% BSA; R&D Systems, UK). Membranes
were washed, incubated with the HRP-linked second-
ary antibody (1:1000; anti-mouse IgG; Sigma, UK)
Immunoreactive bands were detected with ECL (GE
Healthcare, UK) chemiluminescence. Membranes were
then stripped with Re-blot (Re-blot Plus Strong Solu-
tion; Chemicon, UK) for 10 min at room temperature
(1:10 dilution; Chemicon International, US) and probed
for actin expression (Sigma, UK). Bands were quanti-
fied relative to the endogenous control using densito-
metry (Labworks, UVP BioImaging Systems, UK).
Analysis of IFNg and IL-2
Cytokines were assessed by ELISA in hippocampal tissue
prepared from rats and, in the case of IFNg,a l s oi na
human NK cell line. For IFNg, 96-well plates were
coated with monoclonal mouse anti-rat or anti-human
antibody. Pre-coated 96-well plates (BioSource, US)
were used for analysis of IL-2. Samples or standards,
and subsequently detection antibody (biotinylated goat
anti-rat or anti-human antibody), were added and after
incubation in the presence of streptavidin-horseredish
peroxidase, substrate solution was added [2]. Cytokine
concentrations were evaluated with reference to stan-
dard curves.
Statistical analysis
Data were analyzed using either Student’st - t e s tf o r
independent means, or a 1 way ANOVA followed by
post hoc Student Newman-Keuls test. Data are
expressed as means of between 5 and 7 replicates
(± SEM).
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Age increases microglial activation and IFNg production
in the brain
Here we assessed expression of cell surface markers of
microglial activation, and demonstrate age-related
increases in MHCII and CD11b mRNA in hippocampal
tissue, consolidating earlier findings [10,11]. These
changes are accompanied by significant increases in
IFNg mRNA and protein (p < 0.05 or p < 0.01; student’s
t-test for independent means; Figure 1A-D). IFNg is a
potent activator of microglia [12,13] and, consistent
with this, we show that incubation of mixed glia in the
presence of IFNg significantly increased MHCII and
CD11b mRNA (p < 0.05 or p < 0.01; student’st - t e s t ;
Figure 1E, F).
Age increases IFNg producing-CD161
+ NK cells in the
brain
The resident cell source of IFNg in brain remains
unclear. In numerous experiments, we have been unable
to stimulate its release with IL-12, IL-2 and IL-18, or
LPS from cultured mixed glia or neurons; however, one
possible cell source of IFNg is NK cells. The data pre-
sented here indicate that there was an age-related
increase in the number of CD161
+ NKp30
+ cells in the
brain (p < 0.05; student’s t-test; Figure 2A), thus sug-
gesting the specific presence of NK cells. The panel to
the right in Figure 2A shows a sample flow cytometry
plot, demonstrating increased expression of NKp30 in
the aged brain, after gating on the CD161
+ cells.
We prepared CD161
+ cells from hippocampal and
cortical tissue, stimulated them with IL-2 and show that
IFNg release was increased between 2 and 3 fold in each
case (p < 0.05; student’s t-test for independent means;
Figures 2B, C) which compares with significant IL-2-
induced release from a human NK cell line (p < 0.001;
student’s t-test; Figure 2D). However no statistically
significant age-related change in IL-2 was observed
(Figure 2E).
Atorvastatin attenuates age-related and Ab-induced
CD161 expression
The data indicate that there were age-related increases
in expression of CD161 (p < 0.05; ANOVA; Figure 3A)
and another marker of NK cells, NKp46 (Figure 3B).
This was coupled with increased IFNg (p < 0.05;
ANOVA; Figure 3C) in the aged brain and these
changes were attenuated in tissue prepared from aged
rats treated with atorvastatin. Similarly the significant
age-related increases in CD11b and MHCII, and the
chemokines, MCP-1 and IP-10 (p < 0.01 or p < 0.001;
ANOVA; Figure 3D-G), which are chemotactic for NK
cells [14], were also attenuated in hippocampal tissue
prepared from atorvastatin-treated aged rats (p < 0.05 or
p < 0.01; ANOVA).
In parallel, we observed that acute inflammation
induced by intracerebroventricular injection of Ab,
caused a significant increase in expression of CD161
and NKp46 (p < 0.05; ANOVA; Figure 4A, B), This was
again correlated with increased IFNg expression in the
aged brain (p < 0.05; ANOVA; Figure 4C). These
changes were attenuated in tissue prepared from aged
rats treated with atorvastatin (p < 0.05; ANOVA; Figure
4A-C). Ab-induced increases in CD11b and MHCII, and
the chemokines, MCP-1 and IP-10 (p < 0.01 or p <
0.001; ANOVA; Figure 4D-G), were also attenuated in
rats treated with atrovastatin (p < 0.05 or p < 0.001;
ANOVA).
Discussion
The significant and novel findings of this study are that
CD161-positive cells are observed in the brain under
inflammatory conditions, that these cells release IFNg.
This results in microglial activation, and that treatment
of aged or Ab-injected rats with atorvastatin reduces
CD161 and NKp46 expression and the consequent
increases in IFNg and microglial activation.
Age-related increases in MHCII and CD11b presented
here mirror earlier findings [10], as does the parallel
increase in IFNg [12]. It is well known that IFNg
increases microglial activation and its effect on MHCII
and CD11b is similar to that described elsewhere [12],
however, key questions remain as to whether resident
cells in the brain are capable of producing IFNg and
whether endogenous IFNg stimulates microglial activa-
tion. It appears that resident brain cells produce IFNg
only in very specific circumstances. IFNg transcripts
have been identified in human tumour neuroglia and
human astroglial cell lines [15] and in microglia pre-
pared from athymic nude and scid mice infected with
Toxoplasma gondii [4]. However, we have been unable
to detect release of IFNg from cultured glia or neurons
following stimulation with LPS or with IL-2, IL-12 or
IL-18 alone or in combination with LPS. Therefore, we
have considered that NK cells, which are known to be a
major source of IFNg, might be present in brain and
t h a tt h e s ec e l l sm a yb eas o u r c eo fI F N g. The data pre-
sented here show the presence of NK cell markers,
CD161 and NKp46 in the aged hippocampus. The pre-
sence of NK cells was then further suggested by flow
cytomerty, showing increased numbers of CD161
+NKp30
+ cells in the aged hippocampus.
CD161 is one of the archetypal markers of NK cells,
and NKp30 and NKp46 are activating receptors present
on the surface of NK cells [16]. However, it is acknowl-
edged that CD161 is also on a subset of CD4
+ and CD8
+
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concentration were significantly increased in hippocampal tissue prepared from aged compared with young rats (*p < 0.05; **p < 0.01; student’s
t-test for independent means; n = 5-7). E, IFNg (50 ng/ml) significantly increased MHCII mRNA and F, CD11b mRNA in cultured glia in vitro.
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Figure 2 Age-related NK cell infiltration into the brain. A, CD161
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only present in very low numbers in brain [18]. These
data presented here suggest that infiltration of cells
occurs more readily in the brain of aged and Ab-treated
rats compared with young rats. This may be a conse-
quence of the reported inflammatory-mediated increase
in blood brain barrier (BBB) permeability [19], an
increased change in molecules chemotactic for NK cells
or both. Interestingly the age-related and Ab-induced
increase in CD161 and NKp46 is paralleled by increased
hippocampal expression of IP-10 and MCP-1, both of
which have been shown to promote chemotaxis of NK
cells [14,20].
IL-2, IL-12 and IL-18 all potently stimulate release of
IFNg from NK cells [21] and here we show that IL-2
increases IFNg release from CD161
+ cells prepared from
cortex and hippocampus. However, IL-2 expression in
hippocampus was not altered significantly with age sug-
gesting that the increase in IFNg results from the
increased infiltration of NK cells into the brain rather
than any change caused by IL-2.
Atorvastatin decreased CD161 and NKp46 expression
in the brain of aged rats, suggesting that NK cell numbers
in the brain may be decreased. Interestingly atorvastatin
has been shown to increase patency of the BBB in a
hypertension model, by increasing expression of two
tight junction proteins, zonula occludens-1 and occludin
[22]. The present findings, which indicate that atorvasta-
tin decreased the age-related expression of MCP-1 and
IP-10, suggest that the atorvastatin-induced loss of the
chemotactic signal may also contribute to the reduction
in CD161 and NKp46. Consistent with our proposal that
IFNg, derived from NK cells, contributes to microglial
activation in the brain of aged rats, we show that the
atorvastatin-associated change in CD161 and NKp46 was
accompanied by an attenuation of the age-related
changes in MHCII, CD11b and IFNg; these changes pre-
cisely mirror our earlier observations [3]. It is interesting
to note that atorvastatin treatment alone caused a slight
increase in expression of CD161, CD11b, MHCII, and IP-
10, although this increase did not reach statistical signifi-
cance; these effects are apparently independent of IFNg
and NKp46. One possibility may be that atorvastatin
decreased coenzyme Q10 expression which is known to
increase inflammation [23]. The fact that these chages
were evidence only when rats were treated with atorvas-
tatin for 8 weeks, rather than 3 weeks, reflects the finding
that changes in coenzyme Q10 appear to be dependent
on the type of statin used and the duration of the treat-
ment {Marcoff, 2007 #1940}.
The age-related increase in CD161 and NKp46 was
replicated by intracerebroventricular injection of Ab,
suggesting that NK cells also infiltrate the brain in this
model. BBB permeability has been shown to be
compromised in a mouse model of Alzheimer’sd i s e a s e
[24], while soluble Ab has been shown to stimulate
inflammatory changes in the vasculature [25] and to
permit monocyte infiltration into the brain [26]. The
Ab-induced increase in CD161 and NKp46 was paral-
leled by microglial activation and chemokine production,
mirroring the age-related changes. Atorvastatin attenu-
ated the Ab-induced changes as it did the age-related
changes, and this replicates some of our earlier findings
[7]. The modulatory effects of atorvastatin on microglial
activation may provide some insight into why epidemio-
logical evidence suggests that statins reduce the inci-
dence of AD; one possibility is that its primary effect is
on correcting any compromise in BBB permeability [22]
and consequently prevents infiltration of NK cells, that
lead to subsequent microglial activation and inflamma-
tory changes.
Conclusion
The findings described here provide the first evidence
that cells which have a number of phenotypic character-
istics of NK cells are present in the aged brain, and the
data suggest that these cells may release IFNg which
acts to stimulate microglial activation. This microglial
activation can be reversed by treatment with atorvastatin
which works by down-regulating the expression of IP-10
and MCP-1, chemoattractant molecules for NK cells.
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